Review: Preclinical Rheumatoid Arthritis: Progress Toward Prevention

Mankia, Kulveer; Emery, Paul

doi:10.1002/art.39603

Cited by 85 publications

(66 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been shown that early initiation of disease-modifying antirheumatic drug (DMARD) treatment in RA is more effective in modulating the erosive and persisting nature of RA compared with delayed initiation of DMARD treatment 7–9. Hence, interventions in the initial clinical phase of the disease, which precedes the onset of clinical arthritis, may be more effective in reducing the risk of disease persistence and the development of damage 10. However, studies to address this require the inclusion of homogeneous sets of patients.…”

Section: Introductionmentioning

confidence: 99%

EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis

et al. 2016

View full text Add to dashboard Cite

Background During the transition to rheumatoid arthritis (RA) many patients pass through a phase characterised by the presence of symptoms without clinically apparent synovitis. These symptoms are not well-characterised. This taskforce aimed to define the clinical characteristics of patients with arthralgia who are considered at risk for RA by experts based on their clinical experience. Methods The taskforce consisted of 18 rheumatologists, 1 methodologist, 2 patients, 3 health professionals and 1 research fellow. The process had three phases. In phase I, a list of parameters considered characteristic for clinically suspect arthralgia (CSA) was derived; the most important parameters were selected by a three-phased Delphi approach. In phase II, the experts evaluated 50 existing patients on paper, classified them as CSA/no-CSA and indicated their level of confidence. A provisional set of parameters was derived. This was studied for validation in phase III, where all rheumatologists collected patients with and without CSA from their outpatient clinics. Results The comprehensive list consisted of 55 parameters, of which 16 were considered most important. A multivariable model based on the data from phase II identified seven relevant parameters: symptom duration <1 year, symptoms of metacarpophalangeal (MCP) joints, morning stiffness duration ≥60 min, most severe symptoms in early morning, first-degree relative with RA, difficulty with making a fist and positive squeeze test of MCP joints. In phase III, the combination of these parameters was accurate in identifying patients with arthralgia who were considered at risk of developing RA (area under the receiver operating characteristic curve 0.92, 95% CI 0.87 to 0.96). Test characteristics for different cut-off points were determined. Conclusions A set of clinical characteristics for patients with arthralgia who are at risk of progression to RA was established.

show abstract

Section: Introductionmentioning

confidence: 99%

EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…This is followed by asymptomatic synovitis, development of symptoms, a transition to clinically apparent RA and subsequent diagnosis, and then a chronic inflammatory phase. [6][7][8] The preclinical phase of RA is supported by studies identifying the presence of autoantibodies ≥10 years prior to presentation of clinically apparent disease in RA. 9 In this issue of the Annals of Rheumatic Disease, Kristensen et al 10 provide a population-based description of the period leading up to the diagnosis of PsA, potentially the 'preclinical phase' of PsA in their paper 'Societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis'.…”

mentioning

confidence: 99%

The preclinical phase of PsA: a challenge for the epidemiologist

Ogdie

2017

Ann Rheum Dis

View full text Add to dashboard Cite

“…Речь идет о возможности замедления или даже предотвращении трансформации раннего артрита в РА, т. е. фактически о вторичной профи-лактике РА [122][123][124][125] (табл. 3).…”

Section: Discussionunclassified

The 2016 Eular Guidelines for the Diagnosis and Treatment of Early Arthritis

Насонов¹

2017

rsp

View full text Add to dashboard Cite

Review: Preclinical Rheumatoid Arthritis: Progress Toward Prevention

Cited by 85 publications

References 69 publications

EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis

EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis

The preclinical phase of PsA: a challenge for the epidemiologist

The 2016 Eular Guidelines for the Diagnosis and Treatment of Early Arthritis

Contact Info

Product

Resources

About